The CDKN2A (p16) gene and human cancer

Area of Science:

• Genetics and Molecular Biology
• Cancer Research
• Human Genetics

Background:

• The CDKN2A gene, identified in 1994, encodes the p16CDKN2A cell-cycle inhibitor.
• Somatic mutations in CDKN2A are prevalent across numerous cancer types.
• Germline alterations are observed in families with familial atypical multiple mole/melanoma (FAMMM) syndrome.

Purpose of the Study:

• To review and tabulate known mutations in the CDKN2A gene.
• To discuss the implications of germline mutations in CDKN2A.
• To explore the relationship between CDKN2A alterations and cancer predisposition.

Main Methods:

• Comprehensive literature review of CDKN2A mutations.
• Tabulation of identified somatic and germline mutations.
• Analysis of mutation data in the context of cancer predisposition syndromes.

Main Results:

• A comprehensive catalog of known CDKN2A mutations is presented.
• Germline mutations are significantly associated with FAMMM and increased melanoma risk.
• Somatic mutations highlight CDKN2A's role as a tumor suppressor in diverse cancers.

Conclusions:

• CDKN2A mutations play a critical role in both sporadic cancers and hereditary cancer syndromes.
• Understanding CDKN2A germline alterations is crucial for genetic counseling and risk assessment in FAMMM kindreds.
• Further research into CDKN2A's functional impact can inform targeted cancer therapies.